Norvēģija -
norvēģu -
Statens legemiddelverk
hypotron 5 mg
brancaster pharma ireland ltd. - midodrinhydroklorid - tablett - 5 mg
Norvēģija -
norvēģu -
Statens legemiddelverk
hypotron 2.5 mg
brancaster pharma ireland ltd. - midodrinhydroklorid - tablett - 2.5 mg
Norvēģija -
norvēģu -
Statens legemiddelverk
uvadex 20 mikrog/ ml
therakos europe ltd - metoksalen - oppløsning til blodfraksjonsmodifisering - 20 mikrog/ ml
Eiropas Savienība -
norvēģu -
EMA (European Medicines Agency)
sarclisa
sanofi winthrop industrie - isatuximab - multippelt myelom - antineoplastiske midler - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
Norvēģija -
norvēģu -
Statens legemiddelverk
cloxacillin navamedic 2 g
navamedic asa - kloksacillinnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 2 g
Norvēģija -
norvēģu -
Statens legemiddelverk
cloxacillin navamedic 1 g
navamedic asa - kloksacillinnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 1 g
Norvēģija -
norvēģu -
Statens legemiddelverk
cloxacillin stragen 2 g
stragen nordic a/s - kloksacillinnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 2 g
Norvēģija -
norvēģu -
Statens legemiddelverk
cloxacillin stragen 1 g
stragen nordic a/s - kloksacillinnatrium - pulver til injeksjons-/infusjonsvæske, oppløsning - 1 g
Norvēģija -
norvēģu -
Statens legemiddelverk
hypotron 10 mg
brancaster pharma ireland ltd. - midodrinhydroklorid - tablett - 10 mg
Norvēģija -
norvēģu -
Statens legemiddelverk
wakix 4.5 mg
paranova as - pitolisanthydroklorid - tablett, filmdrasjert - 4.5 mg